NASDAQ:ACIU AC Immune Q3 2026 Earnings Results & Report $2.13 +0.04 (+1.67%) Closing price 11/19/2026 03:59 PM EasternExtended Trading$2.11 -0.02 (-1.12%) As of 05:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. AC Immune beat analyst expectations on both earnings and revenue in its Q3 2026 results, released November 4, 2026. The company reported EPS of -$0.16 versus the -$0.18 consensus estimate, while revenue of $3.88 million topped the $1.62 million estimate by $2.26 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 4, 2026TimeBefore Market OpensConference Call7:00 AM ET AC Immune EPS ResultsActual EPS-$0.16Consensus EPS -$0.18Beat/MissBeat by +$0.02One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersAC Immune Revenue ResultsActual Revenue$3.88 millionExpected Revenue$1.62 millionBeat/MissBeat by +$2.26 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (6-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K) AC Immune Q3 2026 Earnings FAQ Did AC Immune beat earnings estimates for Q3 2026? AC Immune (NASDAQ:ACIU) reported earnings of -$0.16 per share for Q3 2026, beating the consensus estimate of -$0.18. The report was announced on Wednesday, November 4, 2026. What was AC Immune's revenue for Q3 2026? AC Immune reported revenue of $3.88 million for Q3 2026, against a consensus estimate of $1.62 million. AC Immune Earnings HeadlinesAC Immune to Present at Jefferies Global Healthcare Conference 2026November 11, 2026 | globenewswire.comHC Wainwright Comments on AC Immune FY2026 EarningsNovember 9, 2026 | americanbankingnews.com“Madam President” [Pic inside]Former CIA and Presidential advisor Jim Rickards says President Trump has a big surprise coming, despite the lame duck label. He calls it Trump's grand finale. Rickards says no president has made this move on the way out the door in more than 100 years, and the new Congress could be powerless to stop it. It centers on a fortune he estimates at $150 trillion. | Paradigm Press (Ad)AC Immune Reports Q3 Clinical Progress and CHF 73.9 Million Cash ResourcesNovember 4, 2026 | tipranks.comAC Immune Third Quarter 2026 Financial and Corporate UpdateNovember 4, 2026 | globenewswire.comAC Immune Adds Tom Graney to Board Following Extraordinary General MeetingOctober 2, 2026 | tipranks.comSee More AC Immune Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like AC Immune? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AC Immune and other key companies, straight to your email. Email Address About AC ImmuneAC Immune (NASDAQ:ACIU) SA is a Swiss biopharmaceutical company focused on developing precision medicines and diagnostic products for neurodegenerative diseases. Its research programs address conditions including Alzheimer’s and Parkinson’s diseases, as well as other neurological disorders. The company’s pipeline includes immunotherapies and small-molecule drug candidates designed to target proteins associated with neurodegeneration. AC Immune also develops diagnostic approaches and uses proprietary technology platforms, including SupraAntigen and Morphomer, to identify and advance potential treatments. Founded in 2003 and headquartered in Lausanne, Switzerland, AC Immune conducts research and clinical development through its own programs and collaborations with pharmaceutical and biotechnology partners. Co-founder Andrea Pfeifer serves as chief executive officer.View AC Immune ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play ItLowe's Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the MathApple's Next Margin Defense Could Be Hiding in Your WalletThe Uranium Price Paradox: 5 Investments Facing Very Different Tests in 2027Target Stock Is Up Over 70%—Has the Easy Money Already Been Made? Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.